文献速递系统性红斑狼疮

芬兰2000-2015年新发SLE患者与人群对照的死亡率比较

Mortality in SLE patients compared with population controls in Finland in years 2000-2015.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于芬兰国家登记数据库,纳入2000至2014年新发成人SLE患者1006例及匹配人群对照3005例,随访至死亡或2015年底。SLE患者粗死亡风险比为1.61,调整基线合并症与教育水平后差异消失(HR 1.14,95%CI 0.88-1.48),提示死亡率增高与诊断时合并症高度相关。

要点

  • SLE患者5年、10年和15年生存率分别为95.0%、88.8%和82.1%。
  • 粗死亡风险比为1.61,调整合并症与教育后降至1.14且无统计学意义。
  • 主要死因为心血管疾病(33%)、恶性肿瘤(27%)和神经系统疾病(10%)。

核心结论

  • SLE患者死亡率增高与诊断时存在的合并症高度相关。
  • 强调应积极筛查和治疗合并症及疾病本身,避免延误。

研究设计与样本

  • 基于芬兰国家药品报销登记和人口登记中心的全国性队列研究。
  • 死亡数据来自国家死因登记,合并症和教育水平通过链接其他国家登记获取。

主要发现

  • SLE患者5年、10年和15年生存率分别为95.0%(95%CI 93.3-96.2)、88.8%(95%CI 86.2-91.0)和82.1%(95%CI 77.6-85.8)。
  • 粗死亡风险比为1.61(95%CI 1.26-2.06),仅调整教育水平后几乎相同为1.61(95%CI 1.26-2.05)。
  • 调整基线合并症和教育水平后死亡率差异消失,HR为1.14(95%CI 0.88-1.48)。
  • 主要死因为心血管疾病(33%)、恶性肿瘤(27%)和神经系统疾病(10%)。
  • 心血管疾病死亡亚风险比为1.28(95%CI 0.85-1.93),调整合并症和教育后为0.88(95%CI 0.56-1.39)。

关键数值与推荐

  • SLE患者粗死亡风险比为1.61(95%CI 1.26-2.06),调整合并症和教育后为1.14(95%CI 0.88-1.48)。
  • 心血管疾病死亡亚风险比粗值为1.28(95%CI 0.85-1.93),调整后为0.88(95%CI 0.56-1.39)。
  • 5年、10年和15年生存率分别为95.0%(95%CI 93.3-96.2)、88.8%(95%CI 86.2-91.0)和82.1%(95%CI 77.6-85.8)。

临床怎么用

  • 对SLE患者应在诊断时全面评估合并症,并积极筛查和治疗。
  • 合并症管理可能缩小SLE患者与一般人群的死亡率差异。
  • 需关注心血管疾病、恶性肿瘤和神经系统疾病作为主要死因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the risk of mortality in the Finnish incident SLE cohort in a 16-year period compared with the general population. METHODS: Adults with new-onset SLE between 1 January 2000 and 31 December 2014 identified from the national drug reimbursement register and their individually matched controls from the Population Register Centre were followed up until death or 31 December 2015. Data on deaths were retrieved from the national causes of death register. Comorbidities and education were obtained by linkage to the other national registries. RESULTS: A total of 1006 patients with incident SLE and 3005 population controls were found (mean follow-up 8.6 years). Of these, 98 SLE patients subsequently died. Their 5 -, 10-, and 15-year survival rates were 95.0% (95% CI: 93.3, 96.2), 88.8% (86.2, 91.0), and 82.1% (77.6, 85.8), respectively. Crude hazard ratio (HR) was 1.61 (95% CI: 1.26, 2.06), adjusted for education level was almost the same 1.61 (95% CI: 1.26, 2.05). After adjustment for comorbidities and education at baseline, the difference in mortality disappeared: HR 1.14 (95% CI: 0.88, 1.48). The leading causes of death were cardiovascular diseases (CVDs) (33%), malignancies (27%) and neurological diseases (10%). Subhazard ratio for CVD deaths was 1.28 (95% CI: 0.85, 1.93), adjusted for comorbidities and education 0.88 (95% CI: 0.56, 1.39). CONCLUSIONS: These results suggest that the increased mortality in SLE patients is highly associated with comorbidities present at diagnosis. This underlines the importance to screen and treat comorbidities and disease actively without delays.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Elfving P, Kariniemi S, Kautiainen H, et al. Mortality in SLE patients compared with population controls in Finland in years 2000-2015. Rheumatology (Oxford). 2021. PMID: 33404636. doi:10.1093/rheumatology/keaa917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。